Kent-Athlone Pharma Group Joins Medicines for Europe as a Company Member as it prepares for commercial expansion in Continental Europe

The Kent-Athlone Pharma Group, a rapidly expanding specialty pharmaceuticals company, is pleased to announce that the Company has become a full member of Medicines for Europe.

Following the substantial organic growth in the UK and Republic of Ireland in recent years, Kent-Athlone Pharma Group will join Medicines for Europe. This follows the announcement in February 2025 that Athlone Pharma (the commercial affiliate of Kent-Athlone Pharma Group in the Republic of Ireland) has joined Medicines for Ireland.

Athlone Pharma is one of the fastest growing Pharma companies in the Republic of Ireland, since inception just 3 years ago.

This new membership marks an exciting step for Kent-Athlone Pharma Group, aligning the company with an influential organisation dedicated to advancing the pharmaceutical sector across the continent.

The Group Company has an extensive portfolio of products, and a deep pipeline of late-stage assets, which it believes has substantial future commercial potential in Europe.

As a member of Medicines for Europe, Kent-Athlone Pharma Group is committed to supporting the association’s core objectives. Medicines for Europe focuses on ensuring the representation and development of interests for the generic, biosimilar, and value-added medicines industries, both within Europe and beyond.

The Group Company is eager to contribute to the vision of Medicines for Europe, which is driven by five key pillars: Patient, Quality, Value, Sustainability, and Partnership. By aligning with these guiding principles, Kent-Athlone Pharma Group reaffirms its dedication to the long-term sustainability and success of the pharmaceutical industry.

This membership clearly reflects Kent-Athlone Pharma Group’s commitment to advancing healthcare in Europe, demonstrating its dedication to quality, accessibility, and patient centricity. The Group Company is excited about the future and the opportunities this membership brings. By joining Medicines for Europe, the Group Company is poised to strengthen its position in the European pharmaceutical market with the vision to set a standard in excellence and transform healthcare through differentiated and added value pharmaceutical products.

Terry Petersen, Group CEO of Kent-Athlone Pharma Group stated: “Following our significant commercial success in recent years, and organic growth in the UK, and Republic of Ireland, it is a natural step for us to join Medicines for Europe, as we seek to expand our commercial footprint in Europe. We look forward to playing an active role, and collaborating closely with Medicines for Europe, and other leading member pharma companies going forwards, in line with the stated aims of Medicines for Europe, which are closely aligned to our own company Vision & Mission.”

Adrian van den Hoven, Director General at Medicines for Europe stated: "We are very pleased to welcome Kent-Athlone Pharma Group to our association. Their dedication to access, quality, and patient centricity perfectly aligns with our mission to optimise and improve health care. I look forward to working with them for better access in Europe."

Date Published

April 25, 2025

Posted By

Kent Pharma

If you require general information concerning one of our products, including availability, please contact our customer services team:

Contact Us